Department of Neurological Surgery, University of Virginia, Charlottesville, VA 22908, USA.
J Neurosurg. 2013 Aug;119(2):487-93. doi: 10.3171/2013.4.JNS121746. Epub 2013 May 24.
Increasingly, meningiomas are detected incidentally, prior to symptom development. While these lesions are traditionally managed conservatively until symptoms develop or lesion growth occurs, it is conceivable that patients at high risk for symptom development may benefit from earlier intervention prior to the appearance of symptoms. However, little research has been performed to determine whether Gamma Knife surgery (GKS) can alter the rate of symptom development in such patients.
A retrospective case study was performed by screening the University of Virginia GKS database for patients treated for asymptomatic meningiomas. From the patient's medical records, pertinent demographic and treatment information was obtained. Yearly follow-up MRI had been performed to assess tumor control and detect signs of radiation-induced injury. Clinical follow-up via neurological examination had been performed to assess symptom development.
Forty-two patients, 33 females (78.6%) and 9 males (21.4%), with 42 asymptomatic meningiomas were included in the analysis. The median age at GKS was 53 years. The most common lesion location was the cerebral convexities (10 lesions [23.8%]), and the median lesion size was 4.0 ml. The median duration of imaging and clinical follow-ups was 59 and 76 months, respectively. During the follow-up period, 1 tumor (2.4%) increased in size, 2 patients (4.8%) demonstrated symptoms, and 1 patient (2.4%) exhibited possible signs of radiation-induced injury. Thus, actuarial tumor control rates were 100%, 95.7%, and 95.7% for 2, 5, and 10 years, respectively. Actuarial symptom control at 5 and 10 years was 97% and 93.1%, respectively. Overall progression-free survival was 91.1% and 77.8% at 5 and 10 years, respectively.
Compared with published rates of symptom development in patients with untreated meningiomas, results in this study indicated that patients with asymptomatic lesions may benefit from prophylactic radiosurgery prior to the appearance of symptoms. Additionally, GKS is a treatment option that offers low morbidity.
越来越多的脑膜瘤是在出现症状之前偶然发现的。虽然这些病变传统上是在出现症状或病变生长之前保守治疗,但可以想象,那些有出现症状高风险的患者可能会从出现症状之前的早期干预中获益。然而,很少有研究来确定伽玛刀手术(GKS)是否可以改变这些患者的症状发展速度。
通过筛选弗吉尼亚大学 GKS 数据库,对无症状脑膜瘤患者进行回顾性病例研究。从患者的病历中获得了相关的人口统计学和治疗信息。每年进行 MRI 随访,以评估肿瘤控制情况并发现放射诱导损伤的迹象。通过神经检查进行临床随访,以评估症状的发展情况。
42 名患者(33 名女性[78.6%]和 9 名男性[21.4%]),42 个无症状脑膜瘤被纳入分析。GKS 的中位年龄为 53 岁。最常见的病变部位是大脑凸面(10 个病变[23.8%]),中位病变大小为 4.0ml。影像学和临床随访的中位时间分别为 59 个月和 76 个月。在随访期间,1 个肿瘤(2.4%)增大,2 名患者(4.8%)出现症状,1 名患者(2.4%)出现可能的放射诱导损伤迹象。因此,2 年、5 年和 10 年的肿瘤控制率分别为 100%、95.7%和 95.7%。5 年和 10 年的症状控制率分别为 97%和 93.1%。总体无进展生存率分别为 5 年和 10 年的 91.1%和 77.8%。
与未经治疗的脑膜瘤患者出现症状的发生率相比,本研究结果表明,无症状病变患者可能会从出现症状之前的预防性放射外科手术中获益。此外,GKS 是一种具有低发病率的治疗选择。